This article refers to:
In the review ‘Emerging drugs for asthma’ by Garry M Walsh, published in the December 2008 issue of Expert Opinion on Emerging Drugs (Expert Opin. Emerging Drugs (2008) 13(4):643-653), it has been bought to our attention that the first sentence of section 2 (page 644) should have read as follows:
The symptoms of most asthmatics are satisfactorily controlled by regular use of inhaled glucocorticoids (GC) with or without the addition of a long-acting β-2 agonist (LABA).
The editors, author and publisher sincerely regret any inconvenience this may have caused the author and our readers.